Compare GSK plc (GSK) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs PepsiCo, Inc. — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while PepsiCo, Inc. trades at $139.15 (market cap $184.81B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.37%). Which is the better fit depends on your goals.
| GSK | PEP | |
|---|---|---|
Market Cap | $101.34B | $184.81B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $170.44 |
52-Week Low | $36.20 | $135.35 |
Enterprise Value | $121.95B | $227.30B |
Dividend Yield | 3.49% | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
PepsiCo (PEP) trades at $139.42, up 2.93% on the day, with a bearish technical signal but strong fundamentals including a 10.78% net income margin and consistent earnings beats. The stock is near its consensus price target of $159.27, with analyst sentiment leaning hold-heavy (64.45%). Recent news highlights price cuts on snacks to boost demand and a North American turnaround focus ahead of Q1 2026 results.
Outlook remains stable with revenue growth to $96.9B in 2026, but risks include competitive pressures and debt levels. The dividend yield near 4% and institutional accumulation support a balanced view, though technical weakness suggests near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
